0000947871-23-000580.txt : 20230613 0000947871-23-000580.hdr.sgml : 20230613 20230515101842 ACCESSION NUMBER: 0000947871-23-000580 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 CORRESP 1 filename1.htm

 

 

By EDGAR

 

May 15, 2023

 

Linda Cvrkel and Suying Li
United States Securities and Exchange Commission

Division of Corporation Finance

Office of Trade and Services

100 F Street, NE
Washington, D.C. 20549-0405

 

 

Re: CVS Health Corporation
 

Form 10-K for Fiscal Year Ended December 31, 2022

Filed February 8, 2023

  File No. 001-01011

 

Dear Mses. Cvrkel and Li:

 

CVS Health Corporation (the “Company”) is responding to the comment letter of the Staff of the U.S. Securities and Exchange Commission (the “Staff”) dated May 11, 2023 on the above referenced filing. For your convenience, we have reproduced the Staff’s comment in bold immediately preceding the Company’s response.

Form 10-K for the Fiscal Year Ended December 31, 2022

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Segment Analysis

Health Care Benefits Segment, page 79

 

1.Your disclosure in the last paragraph on page 80 indicates that “[b]ased on the Company’s membership at December 31, 2022, 21% of the Company’s Medicare Advantage members were in plans with 2023 star ratings of at least 4.0 stars, compared to 87% of the Company’s Medicare Advantage members being in plans with 2022 star ratings of at least 4.0 stars based on the Company’s membership at December 31, 2021.” We also note that your 2023 star ratings will be used to determine which of your Medicare Advantage plans four stars or higher and qualify for bonus payments in 2024. Please revise to quantify, if material, the impact that the significant decline in your plans with four stars or higher could have on your bonus payments in future periods.

 

 

   

 

 

U.S. Securities and Exchange Commission

May 15, 2023

Page 2 of 3

 

We acknowledge the Staff’s comment and respectfully submit that the Company will supplement the disclosures in its Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) to reflect the projected impact of the decline in the percentage of the Company’s Medicare Advantage members in plans with star ratings of at least 4.0 stars in 2023 in the following manner (new disclosure identified in bold and underline):

Medicare Update

...

 

The ACA ties a portion of each Medicare Advantage plan’s reimbursement to the plan’s “star ratings.” Plans must have a star rating of four or higher (out of five) to qualify for bonus payments. CMS released the Company’s 2023 star ratings in October 2022. The Company’s 2023 star ratings will be used to determine which of the Company’s Medicare Advantage plans have ratings of four stars or higher and qualify for bonus payments in 2024. Based on the Company’s membership at December 31, 2022, 21% of the Company’s Medicare Advantage members were in plans with 2023 star ratings of at least 4.0 stars, compared to 87% of the Company’s Medicare Advantage members being in plans with 2022 star ratings of at least 4.0 stars based on the Company’s membership at December 31, 2021. The estimated impact from the decline in the number of Medicare Advantage members in plans with star ratings of at least 4.0 stars, net of mitigating actions, is a reduction of the 2024 operating income of the Health Care Benefits segment of approximately $800 million to $1.0 billion.



In its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2023, the Company announced a realignment of the composition of its segments. In connection with the realignment, the Company expects to file, during the three-month period ending June 30, 2023, a Current Report on Form 8-K (the “Segment Realignment 8-K”) to recast certain prior period financial information to conform with the new segment composition. The Segment Realignment 8-K will include, among other things, the Company’s MD&A for the year ended December 31, 2022 revised to reflect the realignment of the segments as an exhibit. The Company proposes to include the revised disclosure as part of the revised MD&A filed in the Segment Realignment 8-K.

 

If you have any additional questions or comments, please do not hesitate to contact me at Shawn.Guertin@cvshealth.com.

 

Very truly yours,

 

/s/ Shawn M. Guertin

Executive Vice President and Chief Financial Officer

 

cc: James D. Clark, Senior Vice President, Controller and Chief Accounting Officer

 

 

   

 

 

U.S. Securities and Exchange Commission

May 15, 2023

Page 3 of 3

 

Samrat S. Khichi, Executive Vice President, Chief Policy Officer and General Counsel

Colleen M. McIntosh, Senior Vice President, Corporate Secretary and Chief Governance Officer

Lona Nallengara, Shearman & Sterling LLP

 

 

 

 

 

 

 

 

 

 

 

 

 

 GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg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end